San Diego, CA -- (SBWIRE) -- 10/31/2016 -- An investigation on behalf of investors of Juniper Pharmaceuticals Inc shares over potential securities laws violations by Juniper Pharmaceuticals in connection certain financial statements was announced.

Investors who purchased shares of Juniper Pharmaceuticals Inc (NASDAQ:JNP), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Juniper Pharmaceuticals Inc (NASDAQ:JNP) concerning whether a series of statements by Juniper Pharmaceuticals regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On October 24, 2016, Juniper Pharmaceuticals Inc stated in a regulatory filing that its annual statements for 2013 to 2015 as well as its statements for the quarters ended March 31 and June 30, 2016, should no longer be relied upon. Juniper Pharmaceuticals Inc will have to restate its financial statements due to revenue-recognition errors related to a supply agreement with an affiliate of Germany's Merck KGaA.

Shares of Juniper Pharmaceuticals Inc (NASDAQ:JNP) closed on October 28, 2016 at $5.65 per share.

Those who purchased shares of Juniper Pharmaceuticals Inc have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com